Ruogu Gao

Ruogu Gao

Auto-generated profile, based on publicly available information

Ruogu Gao

National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Science
Verified
Journal Article
Closed access
PDF file
Lu ZhangLu Zhang
Lu Zhang
YZYao Zhao
Yao Zhao
YGYan Gao
Yan Gao
LWLijie Wu
Lijie Wu
RGRuogu Gao
Ruogu Gao
ZRZihe Rao
Zihe Rao
Drug inhibition of glycosyltransferases: Mycobacteria, including the species that causes tuberculosis (TB), synthesize a complex cell wall that helps to support and protect the bacterial cells. The major components of the cell wall include complex heteropolysaccharides that are synthesized in the periplasmic space. Zhang et al. determined the cryo–electron microscopy structures of two transmembrane glycosyltransferase enzyme complexes that use a lipid-anchored sugar donor to append arabinose units to the cell wall polysaccharides. They also captured the anti-TB drug ethambutol bound within these complexes and observed that it binds in a site overlapping both donor and acceptor sugars. Mapping of resistance mutants provides a structural understanding of how resistance emerges while preserving function of the enzyme and may help to guide the development of next-generation anti-TB drugs that target these enzymes. Science , this issue p. 1211

27 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
HKHye Jin Kang
Hye Jin Kang
RGRuogu Gao
Ruogu Gao
JWJingjing Wang
Jingjing Wang
GHGye Won Han
Gye Won Han
ZLZhi-Jie Liu
Zhi-Jie Liu
The hydroxycarboxylic acid receptor 2 (HCA2) agonist niacin has been used as treatment for dyslipidemia for several decades albeit with skin flushing as a common side-effect in treated individuals. Extensive efforts have been made to identify HCA2 targeting lipid lowering agents with fewer adverse effects, despite little being known about the molecular basis of HCA2 mediated signalling. Here, we report the cryo-electron microscopy structure of the HCA2-Gi signalling complex with the potent agonist MK-6892, along with crystal structures of HCA2 in inactive state. These structures, together with comprehensive pharmacological analysis, reveal the ligand binding mode and activation and signalling mechanisms of HCA2. This study elucidates the structural determinants essential for HCA2 mediated signalling and provides insights into ligand discovery for HCA2 and related receptors.